Indaptus Therapeutics, Inc. (INDP)

NASDAQ: INDP · Real-Time Price · USD

0.800

+0.029 (3.71%)

Feb 21, 2025, 4:00 PM EST - Market closed

Indaptus Therapeutics Employees

Indaptus Therapeutics had 7 employees as of December 31, 2023. The number of employees increased by 1 or 16.67% compared to the previous year.

Employees

7

Change (1Y)

1

Growth (1Y)

16.67%

Revenue / Employee

n/a

Profits / Employee

-$2,127,680

Market Cap

11.30M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	7	1	16.67%
Dec 31, 2022	6	1	20.00%
Dec 31, 2021	5	3	150.00%
Dec 31, 2020	2	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

INDP News

17 days ago - Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - GlobeNewsWire
6 weeks ago - Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - GlobeNewsWire
3 months ago - Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
3 months ago - Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - GlobeNewsWire
3 months ago - Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - GlobeNewsWire
4 months ago - Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - GlobeNewsWire
10 months ago - Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
11 months ago - Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting - GlobeNewsWire